Xanthine derivatives in the heart: Blessed or cursed?

Current Medicinal Chemistry

Volumn 18, Issue 24, 2011, Pages 3695-3706

  Szentmiklosi A J ^a   Cseppento, A ^a   Gesztelyi, R ^a   Zsuga, J ^a   Kortvely A ^a   Harmati, G ^a   Nanasi P P ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Adenosine; Adenosine receptors; Methylxanthines; Risk benefit ratio; Subtype selectivity; Xanthine derivatives

Indexed keywords

8 (4' CARBOXYMETHYLOXYPHENYL) 1,3 DIPROPYLXANTHINE; 8 (4' CARBOXYMETHYLOXYPHENYL) 1,3 DIPROPYLXANTHINE 2 AMINOETHYLAMIDE; 8 4 (SULPHOPHENYL)THEOPHYLLINE; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; ADENOSINE; ADENOSINE A1 RECEPTOR; ADENOSINE A2A RECEPTOR; ADENOSINE A2B RECEPTOR; ADENOSINE A3 RECEPTOR; ADENOSINE RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; AMINOPHYLLINE; ATL 844; BW A1433U; CAFFEINE; CALCIUM CHANNEL L TYPE; DIURETIC AGENT; GS 6201; HISTONE DEACETYLASE; ISTRADEFYLLINE; METHYLXANTHINE; NAXIFYLLINE; PLACEBO; POTASSIUM; ROLOFYLLINE; ST 1535; THEOPHYLLINE; TONAPOFYLLINE; TOPONAFYLLINE; UNCLASSIFIED DRUG; XANTHINE DERIVATIVE;

ARTICLE; ARTIFICIAL HEART PACEMAKER; ASTHMA; ATRIOVENTRICULAR CONDUCTION; BLOOD BRAIN BARRIER; BRADYCARDIA; CALCIUM CELL LEVEL; CALCIUM CURRENT; CALCIUM TRANSPORT; CARDIOVASCULAR FUNCTION; CONCENTRATION RESPONSE; DIURETIC THERAPY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; EPIGENETICS; GENE SILENCING; GLOMERULUS FILTRATION RATE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART CONDUCTION; HEART DISEASE; HEART ELECTROPHYSIOLOGY; HEART FAILURE; HEART HEMODYNAMICS; HEART MUSCLE; HEART MUSCLE CONDUCTION DISTURBANCE; HEART MUSCLE ISCHEMIA; HEART OUTPUT; HEART PROTECTION; HEART TRANSPLANTATION; HEART VENTRICLE HYPERTROPHY; HUMAN; ISCHEMIC POSTCONDITIONING; ISCHEMIC PRECONDITIONING; KIDNEY DISEASE; NONHUMAN; PACEMAKER; PARKINSON DISEASE; PATHOGENESIS; POSTOPERATIVE COMPLICATION; PROTEIN PROCESSING; PURKINJE FIBER; RECEPTOR BLOCKING; REPERFUSION INJURY; SEIZURE; SICK SINUS SYNDROME; SINOATRIAL CONDUCTION; SINUS BRADYCARDIA; SINUS RHYTHM; STROKE; UPREGULATION;

ACTION POTENTIALS; ANIMALS; CAFFEINE; CARDIOVASCULAR AGENTS; CLINICAL TRIALS AS TOPIC; HEART DISEASES; HUMANS; PURINERGIC P1 RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P1; XANTHINES;

EID: 80051996558     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711796642391     Document Type: Article

References (198)

1. Barnes, P. Theophylline. Pharmaceuticals, 2010, 3, 725-747.
2. Sawynok, J.; Yaksh, T.L. Caffeine as an analgesic adjuvant: a review of pharmacology and mechanisms of action. Pharmacol. Rev., 1993, 45, 43-85. (Pubitemid 23108242)
3. Fredholm, B.B.; Battig, K.; Holmen, J.; Nehlig, A.; Zvartau, E.E. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol. Rev., 1999, 51, 83-133. (Pubitemid 29113867)
4. Riksen, N.P.; Smits, P.; Rongen, G.A. The cardiovascular effects of methylxanthines. Handb. Exp. Pharmacol., 2011, 200, 413-437.
5. Fredholm, B.B. Cardiovascular and renal actions of methylxanthines. Prog. Clin. Biol. Res., 1984, 158, 303-330.
6. Satoh, H. Caffeine depression of spontaneous activity in rabbit sino-atrial node cells. Gen. Pharmacol., 1993, 24, 555-563. (Pubitemid 23179228)
7. Paspa, P.; Vassalle, M. Mechanism of caffeine-induced arrhythmias in canine cardiac Purkinje fibers. Am. J. Cardiol., 1984, 53, 313-319. (Pubitemid 14215377)
8. Lin, C.I.; Chuang, I.N.; Cheng, K.K.; Chiang, B.N. Arrhythmogenic effects of theophylline in human atrial tissue. Int. J. Cardiol., 1987, 17, 289-297. (Pubitemid 17153741)
9. Kimoto, Y. Effects of caffeine on the membrane potentials and contractility of the guinea pig atrium. Jpn. J. Physiol., 1972, 22, 225-238.
10. Yatani, A.; Imoto, Y.; Goto, M. The effects of caffeine on the electrical properties of isolated, single rat ventricular cells. Jpn. J. Physiol., 1984, 34, 337-349. (Pubitemid 14056795)
11. Kamishima, T.; Quayle, J.M. Ca2+-induced Ca2+ release in cardiac and smooth muscle cells. Biochem. Soc. Trans., 2003, 31, 943-946. (Pubitemid 37305022)
12. Eisner, D.A.; Lederer, W.J.; Noble, D. Caffeine and tetracaine abolish the slow inward calcium current in sheep cardiac Purkinje fibres [proceedings]. J. Physiol., 1979, 293, 76P-77P. (Pubitemid 10225528)
13. Hughes, A.D.; Hering, S.; Bolton, T.B. The action of caffeine on inward barium current through voltage-dependent calcium channels in single rabbit ear artery cells. Pflugers Arch., 1990, 416, 462-466. (Pubitemid 20226163)
14. Varro, A.; Hester, S.; Papp, J.G. Caffeine-induced decreases in the inward rectifier potassium and the inward calcium currents in rat ventricular myocytes. B r. J. Pharmacol., 1993, 109, 895-897. (Pubitemid 23216745)
15. Zhang, Y.A.; Tuft, R.A.; Lifshitz, L.M.; Fogarty, K.E.; Singer, J.J.; Zou, H. Caffeine-activated large-conductance plasma membrane cation channels in cardiac myocytes: characteristics and significance. Am. J. Physiol. Heart Circ. Physiol., 2007, 293, H2448-2461. (Pubitemid 47605892)
16. Sattin, A.; Rall, T.W. The effect of adenosine and adenine nucleotides on the cyclic adenosine 3', 5'-phosphate content of guinea pig cerebral cortex slices. Mol. Pharmacol., 1970, 6, 13-23.
17. Fredholm, B.B. Are Methylxanthine Effects Due to Antagonism of Endogenous Adenosine. Trends Pharmacol. Sci., 1980, 1, 129-132.
18. Berne, R.M.; Knabb, R.M.; Ely, S.W.; Rubio, R. Adenosine in the local regulation of blood flow: a brief overview. Fed. Proc., 1983, 42, 3136-3142. (Pubitemid 14204743)
19. Belardinelli, L.; Linden, J.; Berne, R.M. The cardiac effects of adenosine. Prog. Cardiovasc. Dis., 1989, 32, 73-97. (Pubitemid 19175413)
20. Lerman, B.B.; Belardinelli, L. Cardiac electrophysiology of adenosine. Basic and clinical concepts. Circulation, 1991, 83, 1499-1509.
21. Szentmiklosi, A.J.; Nemeth, M.; Szegi, J.; Papp, J.G.; Szekeres, L. On the possible role of adenosine in the hypoxia-induced alterations of the electrical and mechanical activity of the atrial myocardium. Arch. Int. Pharmacodyn. Ther, 1979, 238, 283-295. (Pubitemid 9180866)
22. Szentmiklosi, A.J.; Nemeth, M.; Cseppento, A.; Szegi, J.; Papp, J.G.; Szekeres, L. Effects of hypoxia on the guinea-pig myocardium following inhibition of adenosine deaminase by coformycin. Arch. Int. Pharmacodyn. Ther., 1984, 269, 287-294. (Pubitemid 14116809)
23. Vinten-Johansen, J.; Thourani, V.H.; Ronson, R.S.; Jordan, J.E.; Zhao, Z.Q.; Nakamura, M.; Velez, D.; Guyton, R.A. Broad-spectrum cardioprotection with adenosine. Ann. Thorac. Surg., 1999, 68, 1942-1948.
24. Auchampach, J.A.; Bolli, R. Adenosine receptor subtypes in the heart: therapeutic opportunities and challenges. Am. J. Physiol., 1999, 276, H1113-1116. (Pubitemid 29157489)
25. Norton, G.R.; Woodiwiss, A.J.; McGinn, R.J.; Lorbar, M.; Chung, E.S.; Honeyman, T.W.; Fenton, R.A.; Dobson, J.G., Jr.; Meyer, T.E. Adenosine A1 receptor-mediated antiadrenergic effects are modulated by A2a receptor activation in rat heart. Am. J. Physiol., 1999, 276, H341-349. (Pubitemid 29100599)
26. Dubey, R.K.; Gillespie, D.G.; Jackson, E.K. Adenosine inhibits collagen and protein synthesis in cardiac fibroblasts: role of A2B receptors. Hypertension, 1998, 31, 943-948. (Pubitemid 28185572)
27. Strickler, J.; Jacobson, K.A.; Liang, B.T. Direct preconditioning of cultured chick ventricular myocytes. Novel functions of cardiac adenosine A2a and A3 receptors. J. Clin. Invest., 1996, 98, 1773-1779. (Pubitemid 26359193)
28. Drury, A.N.; Szent-Gyorgyi, A. The physiological activity of adenine compounds with especial reference to their action upon the mammalian heart. J. Physiol., 1929, 68, 213-237.
29. Versprille, A. The chronotropic effect of adenine- and hypoxanthine derivatives on isolated rat hearts before and after removing the sino-auricular node. Pflugers Arch. Gesamte Physiol. Menschen Tiere, 1966, 291, 261-267.
30. DiMarco, J.P.; Sellers, T.D.; Berne, R.M.; West, G.A.; Belardinelli, L. Adenosine: electrophysiologic effects and therapeutic use for terminating paroxysmal supraventricular tachycardia. Circulation, 1983, 68, 1254-1263. (Pubitemid 14207037)
31. Szentmiklosi, A.J.; Nemeth, M.; Szegi, J.; Papp, J.G.; Szekeres, L. Effect of adenosine on sinoatrial and ventricular automaticity of the guinea pig. Naunyn Schmiedebergs Arch. Pharmacol., 1980, 311, 147-149. (Pubitemid 10156679)
32. James, T.N. The chronotropic action of AT P and related compounds studied by direct perfusion of the sinus node. J. Pharmacol. Exp. Ther., 1965, 149, 233-247.
33. Chiba, S.; Hashimoto, K. Differences in chronotropic and dromotropic responses of the SA and AV nodes to adenosine and acetylcholine. Jpn. J. Pharmacol., 1972, 22, 273-274.
34. Urthaler, F.; James, T.N. Effects of adenosine and AT P on AV conduction and on AV junctional rhythm. J. Lab. Clin. Med., 1972, 79, 96-105.
35. Pelleg, A.; Hurt, C.; Miyagawa, A.; Michelson, E.L.; Dreifus, L.S. Differential sensitivity of cardiac pacemakers to exogenous adenosine in vivo. Am. J. Physiol., 1990, 258, H1815-1822. (Pubitemid 20226317)
36. Belardinelli, L.; Isenberg, G. Isolated atrial myocytes: adenosine and acetylcholine increase potassium conductance. Am. J. Physiol., 1983, 244, H734-737. (Pubitemid 13088957)
37. West, G.A.; Belardinelli, L. Correlation of sinus slowing and hyperpolarization caused by adenosine in sinus node. Pflugers Arch., 1985, 403, 75-81. (Pubitemid 15161295)
38. West, G.A.; Belardinelli, L. Sinus slowing and pacemaker shift caused by adenosine in rabbit SA node. Pflugers Arch., 1985, 403, 66-74. (Pubitemid 15161294)
39. Belardinelli, L.; Shryock, J.C.; Song, Y.; Wang, D.; Srinivas, M. Ionic basis of the electrophysiological actions of adenosine on cardiomyocytes. FASEB J., 1995, 9, 359-365.
40. Wang, D.; Belardinelli, L. Mechanism of the negative inotropic effect of adenosine in guinea pig atrial myocytes. Am. J. Physiol., 1994, 267, H2420-2429.
41. Pelleg, A.; Belardinelli, L. Cardiac electrophysiology and pharmacology of adenosine: basic and clinical aspects. Cardiovasc. Res., 1993, 27, 54-61. (Pubitemid 23035666)
42. Honey, R.M.R., W.T.; Thomson, W.A.R. The action of adenosine upon the human heart. Q. J. Med., 1930, 23, 485-490.
43. Watt, A.H. Sick sinus syndrome and adenosine. Lancet, 1985, 1, 1340. (Pubitemid 15059179)
44. Watt, A.H. Sick sinus syndrome: an adenosine-mediated disease. Lancet, 1985, 1, 786-788. (Pubitemid 15103882)
45. Stafford, A. Potentiation of adenosine and the adenine nucleotides by dipyridamole. B r. J. Pharmacol. Chemother., 1966, 28, 218-227.
46. Toft, J.; Mortensen, J.; Hesse, B. Risk of atrioventricular block during adenosine pharmacologic stress testing in heart transplant recipients. Am. J. Cardiol., 1998, 82, 696-697, A699.
47. Harvey, M.G.; Safih, S.; Wallace, M. Adenosine-induced complete heart block: not so transient. Emerg. Med. Australas, 2007, 19, 559-562. (Pubitemid 350132666)
48. Clemo, H.F.; Belardinelli, L. Effect of adenosine on atrioventricular conduction. II: Modulation of atrioventricular node transmission by adenosine in hypoxic isolated guinea pig hearts. Circ. Res., 1986, 59, 437-446. (Pubitemid 17211723)
49. Hollander, P.B.; Webb, J.L. Effects of adenine nucleotides on the contractility and membrane potentials of rat atrium. Circ. Res., 1957, 5, 349-353.
50. Grossman, A.; Furchgott, R.F. The Effects of Various Drugs on Calcium Exchange in the Isolated Guinea-Pig Left Auricle. J. Pharmacol. Exp. Ther., 1964, 145, 162-172.
51. Degubareff, T.; Sleator, W., Jr. Effects of Caffeine on Mammalian Atrial Muscle, and Its Interaction with Adenosine and Calcium. J. Pharmacol. Exp. Ther., 1965, 148, 202-214.
52. Bohm, M.; Meyer, W.; Mugge, A.; Schmitz, W.; Scholz, H. Functional evidence for the existence of adenosine receptors in the human heart. Eur. J. Pharmacol., 1985, 116, 323-326. (Pubitemid 16191825)
53. Collis, M.G. Evidence for an A1-adenosine receptor in the guinea-pig atrium. Br. J. Pharmacol., 1983, 78, 207-212. (Pubitemid 13167597)
54. Szentmiklosi, A.J.; Nemeth, M.; Cseppento, A.; Szegi, J.; Papp, J.G.; Szekeres, L. Potentiation of the myocardial actions of adenosine in the presence of coformycin, a specific inhibitor of adenosine deaminase. Arch. Int. Pharmacodyn. Ther., 1982, 256, 236-252. (Pubitemid 12136226)
55. Jochem, G.; Nawrath, H. Adenosine activates a potassium conductance in guinea-pig atrial heart muscle. Experientia, 1983, 39, 1347-1349. (Pubitemid 14203731)
56. Schrader, J.; Rubio, R.; Berne, R.M. Inhibition of slow action potentials of guinea pig atrial muscle by adenosine: a possible effect on Ca2+ influx. J. Mol. Cell. Cardiol., 1975, 7, 427-433.
57. Fassina, G.; de Biasi, M.; Ragazzi, E.; Caparrotta, L. Adenosine: a natural modulator of L-type calcium channels in atrial myocardium? Pharmacol. Res., 1991, 23, 319-326.
58. Bohm, M.; Bruckner, R.; Hackbarth, I.; Haubitz, B.; Linhart, R.; Meyer, W.; Schmidt, B.; Schmitz, W.; Scholz, H. Adenosine inhibition of catecholamine-induced increase in force of contraction in guinea-pig atrial and ventricular heart preparations. Evidence against a cyclic AMP- and cyclic GMP-dependent effect. J. Pharmacol. Exp. Ther., 1984, 230, 483-492.
59. Bohm, M.; Burmann, H.; Meyer, W.; Nose, M.; Schmitz, W.; Scholz, H. Positive inotropic effect of Bay K 8644: cAMP-independence and lack of inhibitory effect of adenosine. Naunyn Schmiedebergs Arch. Pharmacol., 1985, 329, 447-450. (Pubitemid 15021301)
60. Bruckner, R.; Fenner, A.; Meyer, W.; Nobis, T.M.; Schmitz, W.; Scholz, H. Cardiac effects of adenosine and adenosine analogs in guinea-pig atrial and ventricular preparations: evidence against a role of cyclic AMP and cyclic GMP. J. Pharmacol. Exp. Ther., 1985, 234, 766-774. (Pubitemid 15240561)
61. Buckley, N.M. Cardiac effects of nucleosides after propranolol treatment of isolated hearts. Am. J. Physiol., 1970, 218, 1399-1405.
62. Chiba, S.; Himori, N. Different inotropic responses to adenosine on the atrial and ventricular muscle of the dog heart. Jpn. J. Pharmacol., 1975, 25, 489-491.
63. Schrader, J.; Baumann, G.; Gerlach, E. Adenosine as inhibitor of myocardial effects of catecholamines. Pflugers Arch., 1977, 372, 29-35. (Pubitemid 8226016)
64. Dobson, J.G., Jr. Mechanism of adenosine inhibition of catecholamine-induced responses in heart. Circ. Res., 1983, 52, 151-160. (Pubitemid 13142015)
65. Isenberg, G.; Belardinelli, L. Ionic basis for the antagonism between adenosine and isoproterenol on isolated mammalian ventricular myocytes. Circ. Res., 1984, 55, 309-325. (Pubitemid 14047493)
66. Dobson, J.G., Jr. Reduction by adenosine of the isoproterenol-induced increase in cyclic adenosine 3',5'-monophosphate formation and glycogen phosphorylase activity in rat heart muscle. Circ. Res., 1978, 43, 785-792. (Pubitemid 9054872)
67. Endoh, M.; Yamashita, S. Adenosine antagonizes the positive inotropic action mediated via beta-, but not alpha-adrenoceptors in the rabbit papillary muscle. Eur. J. Pharmacol., 1980, 65, 445-448. (Pubitemid 10034686)
68. Hughes, P.R.; Stone, T.W. Inhibition by purines of the inotropic action of isoprenaline in rat atria. Br. J. Pharmacol., 1983, 80, 149-153. (Pubitemid 13000890)
69. Collis, M.G.; Palmer, D.B.; Saville, V.L. Comparison of the potency of 8-phenyltheophylline as an antagonist at A1 and A2 adenosine receptors in atria and aorta from the guinea-pig. J. Pharm. Pharmacol., 1985, 37, 278-280. (Pubitemid 15149846)
70. Griffith, S.G.; Meghji, P.; Moody, C.J.; Burnstock, G. 8-phenyltheophylline: a potent P1-purinoceptor antagonist. Eur. J. Pharmacol., 1981, 75, 61-64.
71. Collis, M.G.; Jacobson, K.A.; Tomkins, D.M. Apparent affinity of some 8-phenyl-substituted xanthines at adenosine receptors in guinea-pig aorta and atria. B r. J. Pharmacol., 1987, 92, 69-75. (Pubitemid 17122312)
72. Belardinelli, L.; Belloni, F.L.; Rubio, R.; Berne, R.M. Atrioventricular conduction disturbances during hypoxia. Possible role of adenosine in rabbit and guinea pig heart. Circ. Res., 1980, 47, 684-691. (Pubitemid 11238267)
73. Xu, J.; Tong, H.; Wang, L.; Hurt, C.M.; Pelleg, A. Endogenous adenosine, A1 adenosine receptor, and pertussis toxin sensitive guanine nucleotide binding protein mediate hypoxia induced AV nodal conduction block in guinea pig heart in vivo. Cardiovasc. Res., 1993, 27, 134-140. (Pubitemid 23035678)
74. Hayes, E.S. Adenosine receptors and cardiovascular disease: the adenosine-1 receptor (A1) and A1 selective ligands. Cardiovasc. Toxicol., 2003, 3, 71-88. (Pubitemid 37039662)
75. Cseppento, A.; Szentmiklosi, A.J.; Meszaros, J.; Szegi, J. Hypoxia-Induced Changes in the Automaticity of Sino-Atrial Node. Acta Physiol. Acad. Sci. Hung., 1979, 53, 157-157.
76. Brown, L.; Erdmann, E. Concentration-response curves of positive inotropic agents before and after ouabain pretreatment. Cardiovasc. Res., 1985, 19, 288-298. (Pubitemid 15041568)
77. Collis, M.G.; Keddie, J.R.; Torr, S.R. Evidence that the positive inotropic effects of the alkylxanthines are not due to adenosine receptor blockade. B r. J. Pharmacol., 1984, 81, 401-407. (Pubitemid 14149420)
78. Bellemann, P.; Scholz, H. Relationship between theophylline uptake and inotropic effect in the guinea-pig heart. B r. J. Pharmacol., 1974, 52, 265-274.
79. Wu, S.N.; Linden, J.; Visentin, S.; Boykin, M.; Belardinelli, L. Enhanced sensitivity of heart cells to adenosine and up-regulation of receptor number after treatment of guinea pigs with theophylline. Circ. Res., 1989, 65, 1066-1077. (Pubitemid 19242657)
80. Lee, H.T.; Thompson, C.I.; Linden, J.; Belloni, F.L. Differential sensitization of cardiac actions of adenosine in rats after chronic theophylline treatment. Am. J. Physiol., 1993, 264, H1634-1643. (Pubitemid 23154155)
81. von Borstel, R.W.; Wurtman, R.J.; Conlay, L.A. Chronic caffeine consumption potentiates the hypotensive action of circulating adenosine. Life Sci., 1983, 32, 1151-1158. (Pubitemid 13149608)
82. Varani, K.; Portaluppi, F.; Gessi, S.; Merighi, S.; Ongini, E.; Belardinelli, L.; Borea, P.A. Dose and time effects of caffeine intake on human platelet adenosine A(2A) receptors: functional and biochemical aspects. Circulation, 2000, 102, 285-289. (Pubitemid 30457577)
83. Zhang, Y.; Wells, J.N. The effects of chronic caffeine administration on peripheral adenosine receptors. J. Pharmacol. Exp. Ther., 1990, 254, 757-763. (Pubitemid 20303698)
84. Kusaka, H.; Karasawa, A. Effects of repeated administration of KW-3902, a novel adenosine A1-receptor antagonist, on its pharmacological actions. Jpn. J. Pharmacol., 1993, 63, 513-519. (Pubitemid 24008430)
85. Newcombe, P.F.; Renton, K.W.; Rautaharju, P.M.; Spencer, C.A.; Montague, T.J. High-dose caffeine and cardiac rate and rhythm in normal subjects. Chest, 1988, 94, 90-94.
86. Alboni, P.; Ratto, B.; Cappato, R.; Rossi, P.; Gatto, E.; Antonioli, G.E. Clinical effects of oral theophylline in sick sinus syndrome. Am. Heart J., 1991, 122, 1361-1367.
87. Saito, D.; Matsubara, K.; Yamanari, H.; Obayashi, N.; Uchida, S.; Maekawa, K.; Sato, T.; Mizuo, K.; Kobayashi, H.; Haraoka, S. Effects of oral theophylline on sick sinus syndrome. J. Am. Coll. Cardiol., 1993, 21, 1199-1204. (Pubitemid 23106197)
88. Alboni, P.; Menozzi, C.; Brignole, M.; Paparella, N.; Gaggioli, G.; Lolli, G.; Cappato, R. Effects of permanent pacemaker and oral theophylline in sick sinus syndrome the THEOPACE study: a randomized controlled trial. Circulation, 1997, 96, 260-266. (Pubitemid 27298430)
89. Alboni, P.; Rossi, P.; Ratto, B.; Pedroni, P.; Gatto, E.; Antonioli, G.E. Electrophysiologic effects of oral theophylline in sinus bradycardia. Am. J. Cardiol., 1990, 65, 1037-1039. (Pubitemid 20137210)
90. Benditt, D.G.; Benson, D.W., Jr.; Kreitt, J.; Dunnigan, A.; Pritzker, M.R.; Crouse, L.; Scheinman, M.M. Electrophysiologic effects of theophylline in young patients with recurrent symptomatic bradyarrhythmias. Am. J. Cardiol., 1983, 52, 1223-1229. (Pubitemid 14243977)
91. Ling, C.A.; Crouch, M.A. Theophylline for chronic symptomatic bradycardia in the elderly. Ann. Pharmacother., 1998, 32, 837-839. (Pubitemid 28341117)
92. Kragie, L.; Sekovski, B. Theophylline - an alternative therapy for bradyarrhythmia in the elderly. Pharmacotherapy, 1992, 12, 324-330.
93. Heinz, G.; Hirschl, M.; Buxbaum, P.; Laufer, G.; Gasic, S.; Laczkovics, A. Sinus node dysfunction after orthotopic cardiac transplantation: postoperative incidence and long-term implications. Pacing Clin. Electrophysiol., 1992, 15, 731-737.
94. Bertolet, B.D.; Eagle, D.A.; Conti, J.B.; Mills, R.M.; Belardinelli, L. Bradycardia after heart transplantation: reversal with theophylline. J. Am. Coll. Cardiol., 1996, 28, 396-399. (Pubitemid 26274334)
95. Rothman, S.A.; Jeevanandam, V.; Seeber, C.P.; Pina, I.L.; Hsia, H.H.; Bove, A.A.; Miller, J.M. Electrophysiologic effects of intravenous aminophylline in heart transplant recipients with sinus node dysfunction. J. Heart Lung Transplant., 1995, 14, 429-435.
96. Ellenbogen, K.A.; Szentpetery, S.; Katz, M.R. Reversibility of prolonged chronotropic dysfunction with theophylline following orthotopic cardiac transplantation. Am. Heart J., 1988, 116, 202-206.
97. Alboni, P.; Ratto, B.; Scarfo, S.; Rossi, P.; Cappato, R.; Paparella, N. Dromotropic effects of oral theophylline in patients with atrial fibrillation and a slow ventricular response. Eur. Heart J., 1991, 12, 630-634.
98. Cawley, M.J.; Al-Jazairi, A.S.; Stone, E.A. Intravenous theophylline - an alternative to temporary pacing in the management of bradycardia secondary to AV nodal block. Ann. Pharmacother., 2001, 35, 303-307. (Pubitemid 32201714)
99. Bertolet, B.D.; Hill, J.A.; Kerensky, R.A.; Belardinelli, L. Myocardial infarction related atrial fibrillation: role of endogenous adenosine. Heart, 1997, 78, 88-90. (Pubitemid 27346888)
100. Bell, D.G.; Jacobs, I.; Zamecnik, J. Effects of caffeine, ephedrine and their combination on time to exhaustion during high-intensity exercise. Eur. J. Appl. Physiol. Occup. Physiol., 1998, 77, 427-433. (Pubitemid 28154148)
101. Bell, D.G.; McLellan, T.M. Exercise endurance 1, 3, and 6 h after caffeine ingestion in caffeine users and nonusers. J. Appl. Physiol., 2002, 93, 1227-1234.
102. McNaughton, L.R.; Lovell, R.J.; Siegler, J.; Midgley, A.W.; Moore, L.; Bentley, D.J. The effects of caffeine ingestion on time trial cycling performance. Int. J. Sports Physiol. Perform., 2008, 3, 157-163.
103. Sasaki, H.; Takaoka, I.; Ishiko, T. Effects of sucrose or caffeine ingestion on running performance and biochemical responses to endurance running. Int. J. Sports Med., 1987, 8, 203-207. (Pubitemid 17112535)
104. McClaran, S.R.; Wetter, T.J. Low doses of caffeine reduce heart rate during submaximal cycle ergometry. J. Int. Soc. Sports Nutr., 2007, 4, 11.
105. Myers, M.G. Caffeine and cardiac arrhythmias. Ann. Intern. Med., 1991, 114, 147-150.
106. Mukamal, K.J.; Alert, M.; Maclure, M.; Muller, J.E.; Mittleman, M.A. Tea consumption and infarct-related ventricular arrhythmias: the determinants of myocardial infarction onset study. J. Am. Coll. Nutr., 2006, 25, 472-479. (Pubitemid 46175662)
107. Frost, L.; Vestergaard, P. Caffeine and risk of atrial fibrillation or flutter: the Danish Diet, Cancer, and Health Study. Am. J. Clin. Nutr., 2005, 81, 578-582.
108. Graboys, T.B.; Blatt, C.M.; Lown, B. The effect of caffeine on ventricular ectopic activity in patients with malignant ventricular arrhythmia. Arch. Intern. Med., 1989, 149, 637-639. (Pubitemid 19092862)
109. Chelsky, L.B.; Cutler, J.E.; Griffith, K.; Kron, J.; McClelland, J.H.; McAnulty, J.H. Caffeine and ventricular arrhythmias. An electrophysiological approach. JAMA, 1990, 264, 2236-2240. (Pubitemid 20382129)
110. Conrad, K.A.; Prosnitz, E.H. Cardiovascular effects of theophylline. Partial attenuation by beta-blockade. Eur. J. Clin. Pharmacol., 1981, 21, 109-114. (Pubitemid 12239644)
111. Elliott, C.G.; Nietrzeba, R.M.; Adams, T.D.; Crapo, R.O.; Jensen, R.L.; Yanowitz, F.G. Effect of intravenous aminophylline upon the incremental exercise performance of healthy men. Respiration, 1985, 47, 260-266. (Pubitemid 15088754)
112. Conradson, T.B. Bronchodilating plasma concentrations of enprofylline and theophylline have minor cardiovascular effects in man. Acta Pharmacol. Toxicol. (Copenh.), 1986, 58, 204-208.
113. Parker, J.O.; Kelly, G.; West, R.O. Hemodynamic effects of aminophylline in heart failure. Am. J. Cardiol., 1966, 17, 232-239.
114. Parker, J.O.; Kelkar, K.; West, R.O. Hemodynamic effects of aminophylline in cor pulmonale. Circulation, 1966, 33, 17-25.
115. Parker, J.O.; Ashekian, P.B.; Di Giorgi, S.; West, R.O. Hemodynamic effects of aminophylline in chronic obstructive pulmonary disease. Circulation, 1967, 35, 365-372.
116. Howarth, S.; Mc, M.J.; Sharpey-Schafer, E.P. The circulatory action of theophylline ethylene diamine. Clin. Sci. (Lond.), 1947, 6, 125-135.
117. Cosio, B.G.; Soriano, J.B. Theophylline again? Reasons for believing. Eur. Respir. J., 2009, 34, 5-6.
118. Collis, M.G.; Baxter, G.S.; Keddie, J.R. The adenosine receptor antagonist, 8-phenyltheophylline, causes diuresis and saliuresis in the rat. J. Pharm. Pharmacol., 1986, 38, 850-852. (Pubitemid 17179790)
119. Funaya, H.; Kitakaze, M.; Node, K.; Minamino, T.; Komamura, K.; Hori, M. Plasma adenosine levels increase in patients with chronic heart failure. Circulation, 1997, 95, 1363-1365. (Pubitemid 27142790)
120. Gottlieb, S.S. Renal effects of adenosine A1-receptor antagonists in congestive heart failure. Drugs, 2001, 61, 1387-1393. (Pubitemid 32783742)
121. Shryock, J.C.; Belardinelli, L. Adenosine and adenosine receptors in the cardiovascular system: biochemistry, physiology, and pharmacology. Am. J. Cardiol., 1997, 79, 2-10. (Pubitemid 27305162)
122. Lucas, D.G., Jr.; Hendrick, J.W.; Sample, J.A.; Mukherjee, R.; Escobar, G.P.; Smits, G.J.; Crawford, F.A., Jr.; Spinale, F.G. Cardiorenal effects of adenosine subtype 1 (A1) receptor inhibition in an experimental model of heart failure. J. Am. Coll. Surg., 2002, 194, 603-609. (Pubitemid 34496655)
123. Tenstad, O.; Williamson, H.E. Effect of furosemide on local and zonal glomerular filtration rate in the rat kidney. Acta Physiol. Scand., 1995, 155, 99-107.
124. Gottlieb, S.S.; Skettino, S.L.; Wolff, A.; Beckman, E.; Fisher, M.L.; Freudenberger, R.; Gladwell, T.; Marshall, J.; Cines, M.; Bennett, D.; Liittschwager, E.B. Effects of BG9719 (CVT-124), an A1-adenosine receptor antagonist, and furosemide on glomerular filtration rate and natriuresis in patients with congestive heart failure. J. Am. Coll. Cardiol., 2000, 35, 56-59. (Pubitemid 30061259)
125. Gottlieb, S.S.; Brater, D.C.; Thomas, I.; Havranek, E.; Bourge, R.; Goldman, S.; Dyer, F.; Gomez, M.; Bennett, D.; Ticho, B.; Beckman, E.; Abraham, W.T. BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation, 2002, 105, 1348-1353. (Pubitemid 34260427)
126. Cotter, G.; Dittrich, H.C.; Weatherley, B.D.; Bloomfield, D.M.; O'Connor, C.M.; Metra, M.; Massie, B.M. The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment. J. Card. Fail., 2008, 14, 631-640.
127. Massie, B.M.; O'Connor, C.M.; Metra, M.; Ponikowski, P.; Teerlink, J.R.; Cotter, G.; Weatherley, B.D.; Cleland, J.G.; Givertz, M.M.; Voors, A.; DeLucca, P.; Mansoor, G.A.; Salerno, C.M.; Bloomfield, D.M.; Dittrich, H.C. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N. Engl. J. Med., 2010, 363, 1419-1428.
128. Ponikowski, P.; Mitrovic, V.; O'Connor, C.M.; Dittrich, H.; Cotter, G.; Massie, B.M.; Givertz, M.M.; Chen, E.; Murray, M.; Weatherley, B.D.; Fujita, K.P.; Metra, M. Haemodynamic effects of rolofylline in the treatment of patients with heart failure and impaired renal function. Eur. J. Heart Fail., 2010, 12, 1238-1246.
129. Weatherley, B.D.; Cotter, G.; Dittrich, H.C.; DeLucca, P.; Mansoor, G.A.; Bloomfield, D.M.; Ponikowski, P.; O'Connor, C.M.; Metra, M.; Massie, B.M. Design and rationale of the PROTECT study: a placebo-controlled randomized study of the selective A1 adenosine receptor antagonist rolofylline for patients hospitalized with acute decompensated heart failure and volume overload to assess treatment effect on congestion and renal function. J. Card. Fail., 2010, 16, 25-35.
130. Muller, C.E.; Jacobson, K.A. Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochim. Biophys. Acta, 2010.
131. Lim, S.; Tomita, K.; Caramori, G.; Jatakanon, A.; Oliver, B.; Keller, A.; Adcock, I.; Chung, K.F.; Barnes, P.J. Low-dose theophylline reduces eosinophilic inflammation but not exhaled nitric oxide in mild asthma. Am. J. Respir. Crit. Care Med., 2001, 164, 273-276. (Pubitemid 34001294)
132. Hirano, T.; Yamagata, T.; Gohda, M.; Yamagata, Y.; Ichikawa, T.; Yanagisawa, S.; Ueshima, K.; Akamatsu, K.; Nakanishi, M.; Matsunaga, K.; Minakata, Y.; Ichinose, M. Inhibition of reactive nitrogen species production in COPD airways: comparison of inhaled corticosteroid and oral theophylline. Thorax, 2006, 61, 761-766. (Pubitemid 44369399)
133. Cosio, B.G.; Iglesias, A.; Rios, A.; Noguera, A.; Sala, E.; Ito, K.; Barnes, P.J.; Agusti, A. Low-dose theophylline enhances the anti-inflammatory effects of steroids during exacerbations of COPD. Thorax, 2009, 64, 424-429.
134. Ito, K.; Lim, S.; Caramori, G.; Cosio, B.; Chung, K.F.; Adcock, I.M.; Barnes, P.J. A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression. Proc. Natl. Acad. Sci. U S A., 2002, 99, 8921-8926. (Pubitemid 34693659)
135. Barnes, P.J. Theophylline: new perspectives for an old drug. Am. J. Respir. Crit. Care. Med., 2003, 167, 813-818. (Pubitemid 36801766)
136. Kroegel, C. Global Initiative for Asthma (GINA) guidelines: 15 years of application. Expert Rev. Clin. Immunol., 2009, 5, 239-249.
137. Celli, B.R.; MacNee, W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur. Respir. J., 2004, 23, 932-946. (Pubitemid 38807371)
138. Wieshammer, S.; Dreyhaupt, J.; Basler, B. Theophylline and cardiac stress in patients with dyspnea: an observational study. Pharmacology, 2010, 86, 189-195.
139. Riksen, N.P.; Zhou, Z.; Oyen, W.J.; Jaspers, R.; Ramakers, B.P.; Brouwer, R.M.; Boerman, O.C.; Steinmetz, N.; Smits, P.; Rongen, G.A. Caffeine prevents protection in two human models of ischemic preconditioning. J. Am. Coll. Cardiol., 2006, 48, 700-707. (Pubitemid 44175737)
140. Yellon, D.M.; Downey, J.M. Preconditioning the myocardium: from cellular physiology to clinical cardiology. Physiol. Rev., 2003, 83, 1113-1151. (Pubitemid 37222269)
141. Murry, C.E.; Jennings, R.B.; Reimer, K.A. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation, 1986, 74, 1124-1136. (Pubitemid 17174962)
142. Sommerschild, H.T.; Kirkeboen, K.A. Adenosine and cardioprotection during ischaemia and reperfusion - an overview. Acta Anaesthesiol. Scand., 2000, 44, 1038-1055.
143. Liu, G.S.; Thornton, J.; Van Winkle, D.M.; Stanley, A.W.; Olsson, R.A.; Downey, J.M. Protection against infarction afforded by preconditioning is mediated by A1 adenosine receptors in rabbit heart. Circulation, 1991, 84, 350-356.
144. Tsuchida, A.; Miura, T.; Miki, T.; Shimamoto, K.; Iimura, O. Role of adenosine receptor activation in myocardial infarct size limitation by ischaemic preconditioning. Cardiovasc. Res., 1992, 26, 456-461.
145. Auchampach, J.A.; Gross, G.J. Adenosine A1 receptors, KATP channels, and ischemic preconditioning in dogs. Am. J. Physiol., 1993, 264, H1327-1336. (Pubitemid 23154115)
146. Tracey, W.R.; Magee, W.; Masamune, H.; Kennedy, S.P.; Knight, D.R.; Buchholz, R.A.; Hill, R.J. Selective adenosine A3 receptor stimulation reduces ischemic myocardial injury in the rabbit heart. Cardiovasc. Res., 1997, 33, 410-415. (Pubitemid 27075093)
147. Liu, G.S.; Richards, S.C.; Olsson, R.A.; Mullane, K.; Walsh, R.S.; Downey, J.M. Evidence that the adenosine A3 receptor may mediate the protection afforded by preconditioning in the isolated rabbit heart. Cardiovasc. Res., 1994, 28, 1057-1061.
148. Wang, J.; Drake, L.; Sajjadi, F.; Firestein, G.S.; Mullane, K.M.; Bullough, D.A. Dual activation of adenosine A1 and A3 receptors mediates preconditioning of isolated cardiac myocytes. Eur. J. Pharmacol., 1997, 320, 241-248. (Pubitemid 27076752)
149. Hill, R.J.; Oleynek, J.J.; Magee, W.; Knight, D.R.; Tracey, W.R. Relative importance of adenosine A1 and A3 receptors in mediating physiological or pharmacological protection from ischemic myocardial injury in the rabbit heart. J. Mol. Cell. Cardiol., 1998, 30, 579-585. (Pubitemid 28132735)
150. Tomai, F.; Crea, F.; Gaspardone, A.; Versaci, F.; De Paulis, R.; Polisca, P.; Chiariello, L.; Gioffre, P.A. Effects of A1 adenosine receptor blockade by bamiphylline on ischaemic preconditioning during coronary angioplasty. Eur. Heart J., 1996, 17, 846-853. (Pubitemid 26187173)
151. Mitchell, C.H.; Peterson-Yantorno, K.; Carre, D.A.; McGlinn, A.M.; Coca-Prados, M.; Stone, R.A.; Civan, M.M. A3 adenosine receptors regulate Cl-channels of nonpigmented ciliary epithelial cells. Am. J. Physiol., 1999, 276, C659-666. (Pubitemid 29157382)
152. Downey, J.M.; Liu, G.S.; Thornton, J.D. Adenosine and the anti-infarct effects of preconditioning. Cardiovasc. Res., 1993, 27, 3-8.
153. Meijer, P.; Oyen, W.J.; Dekker, D.; van den Broek, P.H.; Wouters, C.W.; Boerman, O.C.; Scheffer, G.J.; Smits, P.; Rongen, G.A. Rosuvastatin increases extracellular adenosine formation in humans in vivo: a new perspective on cardiovascular protection. Arterioscler. Thromb. Vasc. Biol., 2009, 29, 963-968.
154. Schaefer, S.; Correa, S.D.; Valente, R.J.; Laslett, L.J. Blockade of adenosine receptors with aminophylline limits ischemic preconditioning in human beings. Am. Heart J., 2001, 142, E4-E4.
155. Claeys, M.J.; Vrints, C.J.; Bosmans, J.M.; Conraads, V.M.; Snoeck, J.P. Aminophylline inhibits adaptation to ischaemia during angioplasty. Role of adenosine in ischaemic preconditioning. Eur. Heart J., 1996, 17, 539-544. (Pubitemid 26136874)
156. Gaspardone, A.; Crea, F.; Iamele, M.; Tomai, F.; Versaci, F.; Pellegrino, A.; Chiariello, L.; Gioffre, P.A. Bamiphylline improves exercise-induced myocardial ischemia through a novel mechanism of action. Circulation, 1993, 88, 502-508. (Pubitemid 23228049)
157. Zhao, Z.Q.; Corvera, J.S.; Halkos, M.E.; Kerendi, F.; Wang, N.P.; Guyton, R.A.; Vinten-Johansen, J. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am. J. Physiol. Heart Circ. Physiol., 2003, 285, H579-588. (Pubitemid 36885888)
158. Staat, P.; Rioufol, G.; Piot, C.; Cottin, Y.; Cung, T.T.; L'Huillier, I.; Aupetit, J.F.; Bonnefoy, E.; Finet, G.; Andre-Fouet, X.; Ovize, M. Postconditioning the human heart. Circulation, 2005, 112, 2143-2148. (Pubitemid 41475808)
159. Lemoine, S.; Puddu, P.E.; Durand, C.; Lepage, O.; Babatasi, G.; Ivascau, C.; Massetti, M.; Gerard, J.L.; Hanouz, J.L. Signaling pathways involved in postconditioning-induced cardioprotection of human myocardium, in vitro. Exp. Biol. Med. (Maywood), 2010, 235, 768-776.
160. Kin, H.; Zatta, A.J.; Lofye, M.T.; Amerson, B.S.; Halkos, M.E.; Kerendi, F.; Zhao, Z.Q.; Guyton, R.A.; Headrick, J.P.; Vinten-Johansen, J. Postconditioning reduces infarct size via adenosine receptor activation by endogenous adenosine. Cardiovasc. Res., 2005, 67, 124-133. (Pubitemid 40798299)
161. Morrison, R.R.; Tan, X.L.; Ledent, C.; Mustafa, S.J.; Hofmann, P.A. Targeted deletion of A2A adenosine receptors attenuates the protective effects of myocardial postconditioning. Am. J. Physiol. Heart Circ. Physiol., 2007, 293, H2523-2529. (Pubitemid 47605899)
162. Eckle, T.; Krahn, T.; Grenz, A.; Kohler, D.; Mittelbronn, M.; Ledent, C.; Jacobson, M.A.; Osswald, H.; Thompson, L.F.; Unertl, K.; Eltzschig, H.K. Cardioprotection by ecto-5'-nucleotidase (CD73) and A2B adenosine receptors. Circulation, 2007, 115, 1581-1590. (Pubitemid 46648643)
163. Headrick, J.P.; Peart, J.N.; Reichelt, M.E.; Haseler, L.J. Adenosine and its receptors in the heart: Regulation, retaliation and adaptation. Biochim. Biophys. Acta, 2010.
164. Thornton, J.D.; Liu, G.S.; Olsson, R.A.; Downey, J.M. Intravenous pretreatment with A1-selective adenosine analogues protects the heart against infarction. Circulation, 1992, 85, 659-665.
165. Headrick, J.P. Ischemic preconditioning: bioenergetic and metabolic changes and the role of endogenous adenosine. J. Mol. Cell. Cardiol., 1996, 28, 1227-1240. (Pubitemid 26174414)
166. Zhao, Z.Q.; Nakanishi, K.; McGee, D.S.; Tan, P.; Vinten-Johansen, J. A1 receptor mediated myocardial infarct size reduction by endogenous adenosine is exerted primarily during ischaemia. Cardiovasc. Res., 1994, 28, 270-279. (Pubitemid 24092778)
167. Louttit, J.B.; Hunt, A.A.; Maxwell, M.P.; Drew, G.M. The time course of cardioprotection induced by GR79236, a selective adenosine A1-receptor agonist, in myocardial ischaemia-reperfusion injury in the pig. J. Cardiovasc. Pharmacol., 1999, 33, 285-291. (Pubitemid 29066671)
168. Carr, C.S.; Hill, R.J.; Masamune, H.; Kennedy, S.P.; Knight, D.R.; Tracey, W.R.; Yellon, D.M. Evidence for a role for both the adenosine A1 and A3 receptors in protection of isolated human atrial muscle against simulated ischaemia. Cardiovasc. Res., 1997, 36, 52-59. (Pubitemid 27463572)
169. Auchampach, J.A.; Ge, Z.D.; Wan, T.C.; Moore, J.; Gross, G.J. A3 adenosine receptor agonist IB-MECA reduces myocardial ischemia-reperfusion injury in dogs. Am. J. Physiol. Heart Circ. Physiol., 2003, 285, H607-613. (Pubitemid 36885891)
170. Maddock, H.L.; Mocanu, M.M.; Yellon, D.M. Adenosine A(3) receptor activation protects the myocardium from reperfusion/reoxygenation injury. Am. J. Physiol. Heart Circ. Physiol., 2002, 283, H1307-1313.
171. Yang, Z.; Day, Y.J.; Toufektsian, M.C.; Xu, Y.; Ramos, S.I.; Marshall, M.A.; French, B.A.; Linden, J. Myocardial infarct-sparing effect of adenosine A2A receptor activation is due to its action on CD4+ T lymphocytes. Circulation, 2006, 114, 2056-2064. (Pubitemid 44706882)
172. Rork, T.H.; Wallace, K.L.; Kennedy, D.P.; Marshall, M.A.; Lankford, A.R.; Linden, J. Adenosine A2A receptor activation reduces infarct size in the isolated, perfused mouse heart by inhibiting resident cardiac mast cell degranulation. Am. J. Physiol. Heart Circ. Physiol., 2008, 295, H1825-1833.
173. Kuno, A.; Critz, S.D.; Cui, L.; Solodushko, V.; Yang, X.M.; Krahn, T.; Albrecht, B.; Philipp, S.; Cohen, M.V.; Downey, J.M. Protein kinase C protects preconditioned rabbit hearts by increasing sensitivity of adenosine A2b-dependent signaling during early reperfusion. J. Mol. Cell. Cardiol., 2007, 43, 262-271. (Pubitemid 47315714)
174. Headrick, J.P.; Hack, B.; Ashton, K.J. Acute adenosinergic cardioprotection in ischemic-reperfused hearts. Am. J. Physiol. Heart Circ. Physiol., 2003, 285, H1797-1818. (Pubitemid 37305920)
175. Egger, G.; Liang, G.; Aparicio, A.; Jones, P.A. Epigenetics in human disease and prospects for epigenetic therapy. Nature, 2004, 429, 457-463. (Pubitemid 38715140)
176. Bush, E.W.; McKinsey, T.A. Targeting histone deacetylases for heart failure. Expert Opin. Ther. Targets, 2009, 13, 767-784.
177. Kramer, O.H. HDAC2: a critical factor in health and disease. Trends Pharmacol. Sci., 2009, 30, 647-655.
178. McKinsey, T.A. Isoform-selective HDAC inhibitors: Closing in on translational medicine for the heart. J. Mol. Cell. Cardiol., 2010.
179. Kee, H.J.; Kook, H. Roles and targets of class I and IIa histone deacetylases in cardiac hypertrophy. J. Biomed. Biotechnol., 2011, 2011, 928326.
180. Zhang, C.L.; McKinsey, T.A.; Chang, S.; Antos, C.L.; Hill, J.A.; Olson, E.N. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell, 2002, 110, 479-488. (Pubitemid 35232291)
181. Barnes, P.J. Theophylline in chronic obstructive pulmonary disease: new horizons. Proc. Am. Thorac. Soc., 2005, 2, 334-339; discussion 340-331. (Pubitemid 41699692)
182. Cosio, B.G.; Tsaprouni, L.; Ito, K.; Jazrawi, E.; Adcock, I.M.; Barnes, P.J. Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J. Exp. Med., 2004, 200, 689-695. (Pubitemid 39258317)
183. Lutz, J.; Thurmel, K.; Heemann, U. Anti-inflammatory treatment strategies for ischemia/reperfusion injury in transplantation. J. Inflamm. (Lond.), 2010, 7, 27.
184. Walsh, M.C.; Bourcier, T.; Takahashi, K.; Shi, L.; Busche, M.N.; Rother, R.P.; Solomon, S.D.; Ezekowitz, R.A.; Stahl, G.L. Mannose-binding lectin is a regulator of inflammation that accompanies myocardial ischemia and reperfusion injury. J. Immunol., 2005, 175, 541-546. (Pubitemid 40884360)
185. Blancke, F.; Claeys, M.J.; Jorens, P.; Vermeiren, G.; Bosmans, J.; Wuyts, F.L.; Vrints, C.J. Systemic inflammation and reperfusion injury in patients with acute myocardial infarction. Mediators Inflamm., 2005, 2005, 385-389. (Pubitemid 41803408)
186. Werns, S.W.; Lucchesi, B.R. Inflammation and myocardial infarction. B r. Med. Bull., 1987, 43, 460-471. (Pubitemid 17077727)
187. Kaplan, S.; Ozisik, K.; Morgan, J.A.; Dogan, R. Measurement of Troponin T and I to detect cardioprotective effect of aminophylline during coronary artery bypass grafting. Interact. Cardiovasc. Thorac. Surg., 2003, 2, 310-315. (Pubitemid 37040726)
188. Luo, W.J.; Qian, J.F.; Jiang, H.H. Pretreatment with aminophylline reduces release of Troponin I and neutrophil activation in the myocardium of patients undergoing cardioplegic arrest. Eur. J. Cardiothorac. Surg., 2007, 31, 360-365.
189. Fredholm, B.B.; Jacobson, K.A.; Jonzon, B.; Kirk, K.L.; Li, Y.O.; Daly, J.W. Evidence that a novel 8-phenyl-substituted xanthine derivative is a cardioselective adenosine receptor antagonist in vivo. J. Cardiovasc. Pharmacol., 1987, 9, 396-400. (Pubitemid 17052963)
190. Conlay, L.A.; Conant, J.A.; deBros, F.; Wurtman, R. Caffeine alters plasma adenosine levels. Nature, 1997, 389, 136. (Pubitemid 27400589)
191. Riksen, N.P.; Rongen, G.A.; Smits, P. Acute and long-term cardiovascular effects of coffee: implications for coronary heart disease. Pharmacol. Ther., 2009, 121, 185-191.
192. El-Sohemy, A.; Cornelis, M.C.; Kabagambe, E.K.; Campos, H. Coffee, CYP1A2 genotype and risk of myocardial infarction. Genes Nutr., 2007, 2, 155-156.
193. Moro, S.; Gao, Z.G.; Jacobson, K.A.; Spalluto, G. Progress in the pursuit of therapeutic adenosine receptor antagonists. Med. Res. Rev., 2006, 26, 131-159. (Pubitemid 43334639)
194. Baraldi, P.G.; Tabrizi, M.A.; Gessi, S.; Borea, P.A. Adenosine receptor antagonists: translating medicinal chemistry and pharmacology into clinical utility. Chem. Rev., 2008, 108, 238-263. (Pubitemid 351176408)
195. Jacobson, K.A.; Gao, Z.G. Adenosine receptors as therapeutic targets. Nat. Rev. Drug Discov., 2006, 5, 247-264. (Pubitemid 43336037)
196. Kalla, R.V.; Zablocki, J.; Tabrizi, M.A.; Baraldi, P.G. Recent developments in A2B adenosine receptor ligands. Handb. Exp. Pharmacol., 2009, 99-122.
197. Kalla, R.V.; Zablocki, J. Progress in the discovery of selective, high affinity A(2B) adenosine receptor antagonists as clinical candidates. Purinergic Signal., 2009, 5, 21-29.
198. Yang, M.; Soohoo, D.; Soelaiman, S.; Kalla, R.; Zablocki, J.; Chu, N.; Leung, K.; Yao, L.; Diamond, I.; Belardinelli, L.; Shryock, J.C. Characterization of the potency, selectivity, and pharmacokinetic profile for six adenosine A2A receptor antagonists. Naunyn Schmiedebergs Arch. Pharmacol., 2007, 375, 133-144. (Pubitemid 46425343)